A decision-oriented framework for genomic testing across the prostate cancer continuum
Open accessAbstract
Genomic testing is now embedded in contemporary prostate cancer care, yet the clinical meaning of different genomic platforms varies substantially by disease state and clinical context. In localized disease, tissue-based genomic classifiers primarily serve prognostic functions by refining risk estimates beyond clinicopathologic variables, whereas in advanced disease, germline and somatic testing identify predictive biomarkers linked to therapy selection. This distinction is clinically consequential because the supporting evidence, endpoints, and implementation challenges differ across assays and across points on the disease continuum. In this review, we position tissue-based assays, germline testing, somatic sequencing, circulating tumor DNA (ctDNA), and artificial intelligence–enabled biomarkers within a unified clinical framework spanning localized disease, biochemical recurrence, and metastatic progression. We critically compare commercially available genomic assays with respect to methodology, specimen type, intended use, validation cohorts, and clinically relevant outcomes. We distinguish prognostic classifiers from predictive biomarkers such as homologous recombination repair deficiency and mismatch repair deficiency, and we evaluate emerging approaches, including liquid biopsy, multimodal integration with imaging, and digital pathology–based algorithms. We further address implementation barriers that may limit real-world impact, including reimbursement uncertainty, disparities in access to next-generation sequencing, limited provider familiarity with genomic interpretation, and the need for patient-centered communication and navigation in genomics-informed care. A clinically useful framework for prostate cancer genomics must therefore move beyond cataloging tests and instead clarify when genomic results change management, where evidence remains immature, and how implementation strategies can improve equity and actionability.
AI snapshot
Written from the paper’s full text.
TL;DR
This review proposes a decision-oriented framework for using prostate cancer genomic testing according to disease state: prognostic classifiers in localized disease, risk stratification in biochemical recurrence, and predictive biomarkers in metastatic disease. It argues that clinical value depends less on cataloging assays than on aligning each test with a specific management decision, evidence context, and implementation pathway.
Key findings
- Genomic testing should be matched to clinical decision points rather than applied uniformly: tissue-based classifiers mainly refine prognosis in localized disease, while germline and somatic testing identify actionable alterations such as homologous recombination repair deficiency (HRD) and mismatch repair deficiency (dMMR/MSI-H) in advanced disease.
- Germline testing is increasingly relevant therapeutically and familially; a multicenter analysis of 37,184 cases confirmed associations between rare damaging variants in genes such as BRCA2, ATM, and CHEK2 and prostate cancer risk and severity, supporting broader testing beyond restrictive family-history-based criteria.
- Emerging modalities include ctDNA, which can complement tissue sequencing and has independent prognostic value, and AI-enabled digital pathology such as ArteraAI, which has been studied for identifying men with intermediate-risk disease likely to benefit from adding short-term androgen deprivation therapy to radiotherapy.
- Implementation barriers and disparities may limit impact: in a large real-world cohort, Black patients, Hispanic patients, men with lower socioeconomic status, and those with Medicaid or government insurance were less likely to undergo next-generation sequencing for metastatic prostate cancer.
Methods
- Narrative review synthesizing guidelines, randomized trial ancillary studies, systematic reviews, real-world cohorts, and implementation literature across localized disease, biochemical recurrence, and metastatic progression.
- Compares commercially available genomic assays by methodology, specimen type, intended use, validation cohorts, and clinically relevant outcomes, distinguishing prognostic classifiers from predictive biomarkers.
- Proposes a conceptual decision-oriented framework and algorithm for genomic testing across the prostate cancer continuum; no primary data collection or systematic quantitative synthesis is described.
Limitations
- The paper states that evidence remains immature in several areas, including the need for prospective evidence that genomics-guided care improves patient-important outcomes, assay standardization for ctDNA, validation in more diverse populations, and clearer demonstration of clinical utility for localized-disease classifiers.
- The paper states implementation limitations including reimbursement uncertainty, disparities in access to next-generation sequencing, limited provider familiarity with genomic interpretation, inconsistent decision support, and poorly defined handoffs among oncology, pathology, genetics, and supportive care teams.
- Evident from the text: as a narrative review, it does not describe a systematic search strategy, formal quality appraisal, or quantitative synthesis, so its framework reflects expert synthesis rather than a systematic evidence review.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
60 of 87 cited sources checked · 16 supported · 0 flagged · accuracy not yet measured
- Interpretationcitation
These implementation barriers directly influence whether genomic information is translated into a treatment decision, a referral, or a surveillance strategy.
“These are not minor operational challenges; they directly influence whether genomic information is translated into a treatment decision, a referral, or a surveillance strategy [23].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [23] Chen, 2024, Patient navigation in cancer treatment: a systematic review, Curr Oncol Rep source
The Results > Treatment Initiation section (page unavailable) reports that nurse navigation shortened both the time to an EGFR molecular-test result and the time to referral for systemic treatment. The review does not establish that implementation barriers determine whether genomic information is used for a treatment decision, referral, or surveillance strategy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
- Premisecitation
In a landmark study, a multimodal artificial intelligence model derived from digitized histopathology and clinical variables identified men with intermediate-risk disease most likely to benefit from the addition of short-term androgen deprivation therapy to radiotherapy.
“In a landmark study, a multimodal artificial intelligence model derived from digitized histopathology and clinical variables identified men with intermediate-risk disease most likely to benefit from the addition of short-term androgen deprivation therapy to radiotherapy [21].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [21] Wang, 2025, Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer, Radiother Oncol source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
- Premisecitation
In advanced prostate cancer, germline and somatic testing identify predictive biomarkers linked to therapy selection.
“in advanced disease, germline and somatic testing identify predictive biomarkers linked to therapy selection”
- Also stated in: § Genomic Testing Across the Prostate Cancer Continuum · plain
“Germline and somatic sequencing are recommended to identify actionable alterations such as homologous recombination repair deficiency (HRD) and mismatch repair deficiency (dMMR/MSI-H), which have direct implications for PARP inhibitor therapy and immune checkpoint blockade [2, 8–10].”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [2] Yu, 2025, Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline, J Clin Oncol source
- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
- cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
- cites [10] Lenis, 2024, Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer, Clin Cancer Res source
The Methods (Study cohort and Genomic sequencing; page unavailable) describe sequencing tumor and germline DNA and using germline or somatic mismatch-repair alterations to help classify tumors. The Discussion (page unavailable) explicitly supports somatic tumor testing in locally advanced and metastatic prostate cancer to guide immune-checkpoint therapy selection, but does not make the same treatment-selection recommendation for germline testing as a separate test. (LLM, conf=0.84)
Experimental — accuracy not yet measured
- Also stated in: § Genomic Testing Across the Prostate Cancer Continuum · plain
- Interpretationcitation
Such disparities threaten to widen survival gaps precisely as biomarker-directed therapies become more central to standard care.
“Such disparities threaten to widen survival gaps precisely as biomarker-directed therapies become more central to standard care [4, 22].”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
The Conclusions (page unavailable) note that many biomarker-validation results come from White Caucasian cohorts and suggest these tools may be incorporated into future treatment planning. They do not say that disparities threaten to widen survival gaps; they also state that systematic use of the tests is not currently recommended because evidence is insufficient, rather than describing biomarker-directed care as increasingly standard. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [22] Hage Chehade, 2024, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers, JAMA Netw Open source
- Interpretationcitation
Germline, somatic, and liquid biopsy-based approaches are increasingly indispensable in advanced disease, particularly when they identify actionable alterations such as HRD or dMMR.
“In contrast, germline, somatic, and liquid biopsy–based approaches are increasingly indispensable in advanced disease, particularly when they identify actionable alterations such as homologous recombination repair deficiency or mismatch repair deficiency [8–10, 18].”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
Section 3, “Identification of HRD in PC” (page not provided), describes germline, tumor-tissue, and liquid-biopsy tests for HRR alterations that can guide PARP-inhibitor treatment. It also says cfDNA’s role in determining HRR status in prostate cancer remains dubious, so “indispensable” overstates its position. The cited passages do not establish the claim about mismatch repair deficiency. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
The Introduction and section 3.3 support the value of somatic tumor testing for HRD in metastatic castration-resistant prostate cancer: the paper reports that a panel-based HRD signature may help identify patients likely to benefit from olaparib. Section 2.1.1 also describes curation of germline variants, but the paper does not establish that germline testing is increasingly indispensable. The passages do not address liquid biopsy or mismatch repair deficiency, so the full claim is broader than this source supports. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [10] Lenis, 2024, Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer, Clin Cancer Res source
The Introduction (page not available) identifies MSI-H/dMMR prostate cancer as eligible for pembrolizumab, and the Results show that tumor sequencing identified MSI-H/dMMR in a patient who then received immune checkpoint blockade. The Methods describe tumor sequencing with blood as a germline reference, while the Discussion describes liquid biopsy as a possible alternative for detecting MSI-H. The paper does not establish that all three approaches are increasingly indispensable in advanced disease or address homologous recombination repair deficiency as an actionable finding. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [18] Yang, 2024, Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer, iScience source
The Introduction links DNA-repair defects and mismatch-repair deficiency to treatment options in advanced cancer, and the Discussion describes tissue and ctDNA profiling as complementary ways to detect clinically relevant alterations. But the Discussion presents ctDNA’s routine clinical use as a future prospect, not an indispensable approach, and the paper does not establish that germline testing is indispensable. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Premisecitation
A central limitation in current clinical practice is the misalignment between biomarker function and clinical decision context.
“A central limitation in current clinical practice is the misalignment between biomarker function and clinical decision context.”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
The Conclusions describe these biomarkers as prognostic tools and say their specific clinical roles remain uncertain. They also say routine use is not recommended because evidence is insufficient. This supports a limitation in applying biomarkers to clinical decisions, but the paper does not identify a misalignment between biomarker function and decision context as a central limitation. (LLM, conf=0.78)
Experimental — accuracy not yet measured - cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
The Discussion (page unavailable) identifies a mismatch between some genomic-classifier studies and clinical use: 16 of 39 used comparators not typically employed in practice, and some measured biochemical recurrence rather than a more clinically meaningful outcome. Its conclusion calls for evidence more directly relevant to current prostate cancer care. The paper frames this as a limitation of evidence for genomic classifiers in localized prostate cancer, not as a general limitation of current clinical practice or of biomarker function. (LLM, conf=0.82)
Experimental — accuracy not yet measured
- Premisecitation
Clinical implementation programs have identified actionable germline variants even among men without a strong personal or family cancer history.
“while clinical implementation programs have identified actionable germline variants even among men without a strong personal or family cancer history [17].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [17] Mitchell, 2025, Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases, Nat Commun source
The Discussion (page unavailable) describes potential clinical uses of rare germline variants but says these require further study. The Results report genetic associations, not findings from a clinical implementation program. Searches for actionable variants and personal or family cancer history found no passage establishing that such a program identified variants in men without a strong history. (LLM, conf=0.72)
Experimental — accuracy not yet measured
- Premisecitation
In localized prostate cancer, tissue-based genomic classifiers primarily serve prognostic functions by refining risk estimates beyond clinicopathologic variables.
“In localized disease, tissue-based genomic classifiers primarily serve prognostic functions by refining risk estimates beyond clinicopathologic variables”
- Also stated in: § Genomic Testing Across the Prostate Cancer Continuum · plain
“In newly diagnosed localized disease, tissue-based genomic classifiers are generally used to refine baseline risk and guide decisions between active surveillance and definitive treatment [4–7].”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
- cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
- cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
The Introduction (page not provided) describes Decipher as a tissue-based assay developed for prognostication and says it improves risk discrimination beyond clinicopathologic variables. The Discussion reports independent prognostic performance after salvage radiotherapy. The paper supports the claim for Decipher, but does not establish that tissue-based genomic classifiers generally serve primarily prognostic functions across localized prostate cancer. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
- Also stated in: § Genomic Testing Across the Prostate Cancer Continuum · plain
- Premisecitation
Evidence from systematic and implementation studies demonstrates that navigation programs can improve treatment initiation, adherence, and patient satisfaction, particularly in underserved populations.
“Evidence from systematic and implementation studies demonstrates that navigation programs can improve treatment initiation, adherence, and patient satisfaction, particularly in underserved populations [24–26].”
Quote in the paperSubstantial claim3 of 3 sources checked- cites [24] Garfield, 2022, Evaluating the sustainability of patient navigation programs in oncology, Cancer source
The Introduction (page unavailable) reports that patient navigation shortens time to treatment initiation, increases adherence to follow-up after positive cancer screening tests, and improves patient satisfaction. It does not establish improved treatment adherence generally or show that these benefits are particularly pronounced in underserved populations; its reference to vulnerable populations concerns reduced anxiety. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [25] Ver Hoeve, 2022, Implementing patient navigation programs: considerations and lessons learned from the alliance to advance patient-centered cancer care, Cancer source
The Results (Program Highlights; page unavailable) report reduced time to treatment initiation and improved treatment compliance at Alliance sites serving underserved patients. Materials and Methods lists patient satisfaction as an outcome assessed, but the passages do not report an improvement in satisfaction. Thus the source supports treatment initiation and adherence, not all three claimed benefits. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [26] Varanasi, 2024, Patient navigation job roles by levels of experience: workforce development task group, national navigation roundtable, Cancer source
- Premisecitation
Most commercially available tissue-based genomic assays, including Oncotype DX, Prolaris, and Decipher, are based on RNA expression profiling and quantify gene activity associated with proliferation, androgen receptor signaling, and metastatic potential.
“Most commercially available assays, including Oncotype DX, Prolaris, and Decipher, are based on RNA expression profiling and quantify gene activity associated with proliferation, androgen receptor signaling, and metastatic potential [4, 11–13].”
Quote in the paperNot a substantial claim3 of 4 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
- cites [11] Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in men with early-stage disease, Eur Urol
Not checked in the free run.
- cites [12] Cullen, 2015, A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy, Eur Urol source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [13] Cuzick, 2015, Validation of an RNA cell cycle progression score for predicting death from prostate cancer, Br J Cancer source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
- Premisecitation
Oncotype DX and Prolaris are primarily validated in biopsy tissue to inform initial risk stratification and decision-making between active surveillance and definitive treatment.
“Oncotype DX and Prolaris are primarily validated in biopsy tissue to inform initial risk stratification and decision-making between active surveillance and definitive treatment [11–13].”
Quote in the paperSubstantial claim2 of 3 sources checked- cites [11] Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in men with early-stage disease, Eur Urol
Not checked in the free run.
- cites [12] Cullen, 2015, A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy, Eur Urol source
The Conclusions (p. 131) validate the biopsy-based Genomic Prostate Score for risk assessment to guide treatment decisions in men with newly diagnosed prostate cancer. The Introduction (p. 123) frames active surveillance as an alternative to immediate therapy. But this study does not validate Prolaris in biopsy tissue for that decision; the Discussion (p. 129) mentions a 46-gene cell-cycle signature only in relation to longer-term outcomes and says only GPS had been validated to predict adverse pathology. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [13] Cuzick, 2015, Validation of an RNA cell cycle progression score for predicting death from prostate cancer, Br J Cancer source
The Methods (CCP score; page unavailable) link the studied cell-cycle progression assay to Prolaris, and the Discussion (page unavailable) says it can be generated from a diagnostic needle-biopsy core. The Results (Identification of a low-risk group suitable for active surveillance; page unavailable) use the score to identify men at low risk, supporting its relevance to pretreatment decisions. The paper does not address Oncotype DX or establish that both tests are primarily validated in biopsy tissue. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
Many earlier molecular assays failed to achieve widespread adoption due to limited reproducibility, lack of external validation, and unclear incremental value beyond standard clinicopathologic variables.
“Although some demonstrated initial associations with clinical outcomes, many failed to achieve widespread adoption due to limited reproducibility, lack of external validation, and unclear incremental value beyond standard clinicopathologic variables [15, 16].”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [15] Ioannidis, 2005, Why most published research findings are false, PLoS Med source
The ‘Modeling the Framework for False Positive Findings’ section describes a high rate of nonreplication, and Corollary 3 says findings from microarrays and other high-throughput discovery research have a very low probability of being true. That supports concern about reproducibility, but the paper does not say that many earlier molecular assays failed to gain widespread adoption, or identify lack of external validation and unclear incremental value beyond clinicopathologic variables as reasons. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [16] Simon, 2010, Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology, Per Med source
The Prognostic biomarkers passage (labelled Abstract; page unavailable) says that very few published prognostic factors are used in clinical practice. Another Abstract passage says retrospective studies often fail to show predictive value beyond standard prognostic factors. The paper emphasizes reproducibility and rigorous validation, but it does not establish that limited reproducibility and lack of external validation caused earlier molecular assays to go unused. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Premisecitation
In newly diagnosed localized disease, tissue-based genomic classifiers are generally used to refine baseline risk and guide decisions between active surveillance and definitive treatment.
“In newly diagnosed localized disease, tissue-based genomic classifiers are generally used to refine baseline risk and guide decisions between active surveillance and definitive treatment [4–7].”
Quote in the paperNot a substantial claim4 of 4 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
The Conclusions say tissue-based genomic classifiers have been tested in newly diagnosed prostate cancer to refine risk stratification and guide management, including active surveillance decisions. But they also say routine use is not currently recommended because evidence is insufficient, so “generally used” overstates the paper’s position. No page numbers are provided in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
The Introduction (page unavailable) says tissue-based genomic classifiers were developed to refine clinical risk classifications and inform personalized treatment recommendations for localized prostate cancer. It does not establish that they are generally used in newly diagnosed patients specifically to choose between active surveillance and definitive treatment; the Results (page unavailable) say most included studies involved patients who initially underwent prostatectomy. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
The Introduction describes Decipher as a tissue-based assay that aids prostate cancer prognostication. But this study concerns patients receiving salvage radiotherapy after prostatectomy, and the Discussion considers decisions about adding hormone therapy—not decisions between active surveillance and definitive treatment in newly diagnosed localized disease. No page numbers are available in our copy. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
The Introduction (page unavailable) says the Decipher classifier improves risk stratification in intermediate-risk prostate cancer, and the Discussion (page unavailable) describes using its results to inform treatment-intensification decisions. The paper lists active surveillance as a treatment option but does not show that classifiers generally guide the choice between active surveillance and definitive treatment; its trial compared radiation doses in men receiving definitive treatment. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Premisereasoning
The supporting evidence, endpoints, and implementation challenges differ across assays and across points on the disease continuum.
“the supporting evidence, endpoints, and implementation challenges differ across assays and across points on the disease continuum”
Quote in the paperSubstantial claim - Premisecitation
Earlier generations of molecular assays in prostate cancer included smaller candidate-gene panels and early biomarker signatures developed prior to the current emphasis on large-scale validation.
“Earlier generations of molecular assays in prostate cancer included smaller candidate-gene panels and early biomarker signatures that were developed prior to the current emphasis on large-scale validation [6, 11, 14].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
Checked before — its earlier verdict is held back until a new check runs.
- cites [11] Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in men with early-stage disease, Eur Urol
Not checked in the free run.
- cites [14] Blume-Jensen, 2015, Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer, Clin Cancer Res source
- Interpretationcitation
These findings support broader genomic evaluation strategies, particularly in high-risk and metastatic settings.
“These findings support broader genomic evaluation strategies, particularly in high-risk and metastatic settings [2, 3].”
Quote in the paperSubstantial claim0 of 2 sources checked - Premisecitation
A multicenter analysis of 37,184 cases confirmed associations between rare damaging variants in genes such as BRCA2, ATM, and CHEK2 with prostate cancer risk and severity.
“A multicenter analysis of 37,184 cases confirmed associations between rare damaging variants in genes such as BRCA2, ATM, and CHEK2 with prostate cancer risk and severity”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [17] Mitchell, 2025, Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases, Nat Commun source
Checked before — its earlier verdict is held back until a new check runs.
- Premisecitation
Mainstreaming models, in which oncology teams initiate germline testing and genetics specialists focus on complex counseling or management of positive results, are becoming increasingly important as testing demand expands.
“Operationally, mainstreaming models, in which oncology teams initiate germline testing and genetics specialists focus on complex counseling or management of positive results, are becoming increasingly important as testing demand expands [3].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [3] Spratt, 2025, Prostate cancer, version 3.2026, NCCN clinical practice guidelines in oncology, J Natl Compr Canc Netw source
- Premisereasoning
The clinical meaning of different genomic platforms varies substantially by disease state and clinical context.
“the clinical meaning of different genomic platforms varies substantially by disease state and clinical context”
Quote in the paperSubstantial claim - Premisecitation
Successful implementation of mainstreaming models depends on assay literacy, clear referral pathways, and communication structures that ensure pathogenic findings are translated into appropriate therapeutic decisions and familial risk management.
“However, successful implementation depends on assay literacy, clear referral pathways, and communication structures that ensure pathogenic findings are translated into appropriate therapeutic decisions and familial risk management rather than remaining isolated laboratory results [2].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [2] Yu, 2025, Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline, J Clin Oncol source
- Interpretationreasoning
Implementation is not a downstream consideration but a central determinant of whether genomic testing achieves its intended clinical impact.
“These findings highlight that implementation is not a downstream consideration but a central determinant of whether genomic testing achieves its intended clinical impact.”
Quote in the paperSubstantial claim
- May combine two claims. 23
- Classified as probably not a substantial claim. 2
May combine two claims.
InterpretationcitationSubsequent validation in oligometastatic castration-sensitive disease and the prospective ASTuTE implementation protocol suggest that AI-based biomarkers may ultimately influence treatment decisions across multiple disease states, provided that external validation, workflow integration, and real-world utility are demonstrated.
“Subsequent validation in oligometastatic castration-sensitive disease and the prospective ASTuTE implementation protocol suggest that AI-based biomarkers may ultimately influence treatment decisions across multiple disease states, provided that external validation, workflow integration, and real-world utility are demonstrated [22].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [22] Hage Chehade, 2024, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers, JAMA Netw Open source
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
May combine two claims.
InterpretationcitationTissue-based genomic classifiers can improve risk refinement in localized disease, but their incremental utility is context dependent and not uniformly transformative.
“Tissue-based genomic classifiers can improve risk refinement in localized disease, but their incremental utility is context dependent and not uniformly transformative [4–7].”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
- cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
- cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
The Introduction and Discussion (page not provided) say the tissue-based Decipher classifier improves prognostication beyond clinicopathologic factors and adds independent prognostic information after salvage radiotherapy. The Discussion also identifies sample-size and subgroup-analysis limitations. But this study examines a specific post-prostatectomy salvage-radiotherapy setting; it does not establish how much classifiers improve risk refinement across localized disease or compare their incremental utility across contexts. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
Classified as probably not a substantial claim.
PremisecitationIn metastatic disease, germline and somatic sequencing are recommended to identify actionable alterations such as HRD and dMMR/MSI-H, which have direct implications for PARP inhibitor therapy and immune checkpoint blockade.
“In metastatic disease, genomic testing shifts toward predictive biomarkers. Germline and somatic sequencing are recommended to identify actionable alterations such as homologous recombination repair deficiency (HRD) and mismatch repair deficiency (dMMR/MSI-H), which have direct implications for PARP inhibitor therapy and immune checkpoint blockade [2, 8–10].”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [2] Yu, 2025, Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline, J Clin Oncol source
- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
The Introduction and §3 (page numbers unavailable) link germline or somatic HRR alterations in metastatic prostate cancer to PARP inhibitor eligibility and describe tests for identifying them. The paper does not state the broader recommendation to sequence for both HRD and dMMR/MSI-H. §8.2 discusses immune checkpoint inhibitors as investigational combinations with PARP inhibitors, not as a treatment implication of dMMR/MSI-H testing. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
The Introduction (page unavailable) says guidelines recommend germline and somatic testing in high-risk localized or advanced prostate cancer for HRR alterations associated with PARP inhibitor response. The paper also studies HRD as a predictor of olaparib response in metastatic castration-resistant prostate cancer, but the cited passages do not address dMMR/MSI-H or immune checkpoint blockade. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [10] Lenis, 2024, Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer, Clin Cancer Res source
The Discussion (page not provided) says the findings support recommendations for somatic tumor testing in locally advanced and metastatic prostate cancer to guide treatment selection, citing responses to immune checkpoint blockade in MSI-H/dMMR tumors. The Methods describe sequencing blood-derived germline DNA, but the paper does not recommend germline sequencing; nor does it support the claim that identifying HRD guides PARP inhibitor therapy. Its Discussion cautions that some BRCA1/2 mutations observed may not be actionable. (LLM, conf=0.89)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationDecipher has broader validation across both biopsy and prostatectomy contexts and has demonstrated associations with metastasis and prostate cancer-specific mortality, including in randomized trial cohorts.
“Decipher has broader validation across both biopsy and prostatectomy contexts and has demonstrated associations with metastasis and prostate cancer–specific mortality, including in randomized trial cohorts [6, 7].”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
The Introduction and Discussion describe Decipher validation in randomized trial cohorts, and Relevant Oncological Endpoints reports that the classifier was prognostic for all endpoints, including exploratory metastasis endpoints. The tissue analyzed in this study came from prostatectomy specimens; our copy does not establish validation in biopsy specimens or an association with prostate cancer–specific mortality. The indexed passages provide section labels but no page numbers. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
May combine two claims.
PremisecitationIn advanced prostate cancer, ctDNA fraction correlates with disease burden and predicts survival and treatment outcomes across therapeutic contexts.
“In advanced prostate cancer, ctDNA fraction correlates with disease burden and predicts survival and treatment outcomes across therapeutic contexts, suggesting that liquid biopsy can contribute not only to genotyping but also to risk stratification and test triage [19].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [19] Fonseca, 2024, Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer, Nat Commun source
May combine two claims.
PremisecitationPopulation-based data suggest that prostate MRI and genomic testing influence treatment pathways differently, highlighting the need to consider these tools as complementary rather than interchangeable components of risk assessment.
“Population-based data suggest that prostate magnetic resonance imaging (MRI) and genomic testing influence treatment pathways differently, highlighting the need to consider these tools as complementary rather than interchangeable components of risk assessment [9].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
The Introduction and section 3.3 discuss genomic biomarkers for selecting patients with metastatic castration-resistant prostate cancer for PARP-inhibitor treatment. The paper does not compare genomic testing with prostate MRI, establish that they influence treatment pathways differently, or present population-based evidence for treating them as complementary risk-assessment tools. (LLM, conf=0.82)
Experimental — accuracy not yet measured
May combine two claims.
InterpretationcitationMethodological and clinical distinctions among tissue-based genomic classifiers limit direct interchangeability and underscore the importance of selecting tests based on the specific clinical question being addressed.
“These methodological and clinical distinctions limit direct interchangeability among assays and underscore the importance of selecting tests based on the specific clinical question being addressed [4]”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
May combine two claims.
PremisecitationHRD is the most well-established predictive biomarker in advanced prostate cancer, with alterations in BRCA1, BRCA2, and ATM associated with sensitivity to PARP inhibitors.
“HRD represents the most well-established predictive biomarker, with alterations in genes such as BRCA1, BRCA2, and ATM associated with sensitivity to PARP inhibitors [8,9].”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
Section 4 reports the greatest PARP-inhibitor effectiveness in patients with BRCA1/2 alterations, supporting those genes as predictors of response. It says efficacy with alterations in other genes remains uncertain; for ATM, it reports a weaker response in one trial and no objective responses in another. The copy also does not establish HRD as the *most* well-established predictive biomarker. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
The Introduction (page unavailable) says BRCA1/2 alterations strongly associate with PARP-inhibitor response, and Results §3.2 finds that the HRD signature predicts olaparib response in metastatic castration-resistant prostate cancer. But the Introduction says the association for ATM is less clear, while §3.3 says comparable HRD assays in prostate cancer have not been well validated. The source therefore does not support calling HRD the most well-established predictive biomarker or grouping ATM with BRCA1/2 as an established sensitivity marker. (LLM, conf=0.90)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationNational data indicate that use of genomic assays such as Decipher has increased in the United States, but uptake remains uneven and may reflect payer, practice, and regional differences rather than purely evidence-driven diffusion.
“National data indicate that use of genomic assays such as Decipher has increased in the United States, but uptake remains uneven and may reflect payer, practice, and regional differences rather than purely evidence-driven diffusion [8].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
Section 3 (Identification of HRD in PC; page not provided) describes tests for homologous recombination repair status, including FoundationOne CDx and Myriad BRACAnalysis CDx. Searches for Decipher and for genomic-test uptake and reimbursement found no passage about US national utilization trends or payer, practice, and regional differences. (LLM, conf=0.76)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationIn a large real-world cohort, Black patients, Hispanic patients, men with lower socioeconomic status, and those with Medicaid or government insurance were less likely to undergo next-generation sequencing for metastatic prostate cancer.
“In a large real-world cohort, Black patients, Hispanic patients, men with lower socioeconomic status, and those with Medicaid or government insurance were less likely to undergo next-generation sequencing for metastatic prostate cancer [22].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [22] Hage Chehade, 2024, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers, JAMA Netw Open source
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationArtificial intelligence-enabled digital pathology biomarkers are advancing from retrospective validation toward prospective implementation studies.
“In parallel, artificial intelligence–enabled digital pathology biomarkers are advancing from retrospective validation toward prospective implementation studies [21, 22].”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [21] Wang, 2025, Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer, Radiother Oncol source
The Methods and Discussion describe retrospective validation of an AI biomarker using digitized pathology slides, including slides from patients enrolled in prospective trials. The Discussion calls for further validation, but does not describe prospective implementation studies; participation in a prospective trial does not make this biomarker assessment a prospective implementation study. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [22] Hage Chehade, 2024, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers, JAMA Netw Open source
The Introduction and Methods > Patient Selection (page unavailable) concern next-generation sequencing trends and a retrospective electronic-health-record cohort. Searches for AI-enabled digital pathology biomarkers and prospective implementation studies found no passage addressing their progression from retrospective validation. (LLM, conf=0.77)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationIn metastatic hormone-sensitive disease, paired analyses of tissue and ctDNA have identified partially distinct genomic alterations and shown that integrated profiling improves detection of features associated with progression to castration resistance.
“In metastatic hormone-sensitive disease, paired analyses of tissue and ctDNA have identified partially distinct genomic alterations and shown that integrated profiling improves detection of features associated with progression to castration resistance [18].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [18] Yang, 2024, Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer, iScience source
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationPrognostic classifiers are sometimes overinterpreted as treatment-directing tools, while predictive biomarkers with clear therapeutic implications remain underutilized.
“Prognostic classifiers are sometimes overinterpreted as treatment-directing tools, while predictive biomarkers with clear therapeutic implications remain underutilized [4, 5].”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
The Conclusions (p. not provided) describe these classifiers as prognostic tools and caution that evidence is insufficient to recommend their systematic use in prostate cancer. That supports caution about using them to direct treatment, but the paper does not say they are sometimes overinterpreted or that predictive biomarkers with clear therapeutic implications are underutilized. (LLM, conf=0.76)
Experimental — accuracy not yet measured - cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
The Introduction (page unavailable) describes the classifiers as tools for estimating prognosis and says large studies of their predictive ability are still underway. The Discussion (page unavailable) questions the clinical meaning of their modest prognostic improvement. This supports caution about treating prognostic results as treatment-directing evidence, but the paper does not say that clinicians sometimes overinterpret them or that predictive biomarkers with clear therapeutic implications are underutilized. (LLM, conf=0.77)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationTherapeutic benefit from PARP inhibitors is not uniform across HRD genes, with BRCA2 alterations typically conferring the strongest response.
“However, therapeutic benefit is not uniform across genes, with BRCA2 alterations typically conferring the strongest response.”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [8] Piombino, 2024, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities, Int J Mol Sci source
Section 4 (page unavailable) says PARP inhibitors are most effective in patients with BRCA1/2 alterations, compared with alterations in other genes. It does not establish that BRCA2 specifically confers the strongest response: the cited analyses largely group BRCA1 and BRCA2 together, and the separate overall-survival estimates do not favor BRCA2 over BRCA1. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [9] Boiarsky, 2024, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer, Prostate source
May combine two claims.
PremisecitationTissue-based genomic classifiers provide prognostic information regarding adverse pathology, biochemical recurrence, and metastatic risk but generally do not identify specific therapeutic targets.
“These assays provide prognostic information regarding adverse pathology, biochemical recurrence, and metastatic risk but generally do not identify specific therapeutic targets.”
Quote in the paperSubstantial claim4 of 4 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
The Data Synthesis sections on Oncotype (3.5–3.6; page unavailable) report prognostic associations with adverse pathology, biochemical recurrence, and metastasis, and the Conclusions describe these assays as prognostic tools. Our copy does not state that the classifiers generally fail to identify specific therapeutic targets, so that part of the claim is unsupported. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [5] Boyer, 2025, Genomic classifiers and prognosis of localized prostate cancer: a systematic review, Prostate Cancer Prostatic Dis source
The Discussion (page unavailable) reports that genomic classifiers modestly improve prognostic assessment for biochemical recurrence and metastases. The Introduction describes them as tissue-based tests that estimate prognosis. The review does not establish the claimed limitation concerning specific therapeutic targets; adverse pathology appears in cited study titles, but is not established as a reviewed outcome in the passages found. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
The Introduction describes Decipher as a tissue-based assay for prostate cancer prognostication, and the Results report an association with biochemical progression. The paper also evaluates metastasis-related outcomes, but the cited passages do not establish the broader claims about adverse pathology or that these assays generally do not identify specific therapeutic targets. No page numbers are available in our copy. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
The Results and Conclusion report that the biopsy-based Decipher classifier was prognostic for biochemical failure and distant metastasis in men with intermediate-risk prostate cancer. The paper does not establish the broader claim about adverse pathology or say that tissue-based genomic classifiers generally do not identify specific therapeutic targets. (LLM, conf=0.85)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationIn metastatic prostate cancer, next-generation sequencing testing rates have improved but still leave many eligible patients untested.
“Similar concerns apply to next-generation sequencing in metastatic disease, where testing rates have improved but still leave many eligible patients untested [22].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [22] Hage Chehade, 2024, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers, JAMA Netw Open source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
PremisecitationIn biochemical recurrence, genomic classifiers may help identify patients at higher risk of metastatic progression or those who may benefit from treatment intensification in conjunction with salvage therapy.
“In biochemical recurrence, genomic classifiers may help identify patients at higher risk of metastatic progression or those who may benefit from treatment intensification in conjunction with salvage therapy [6, 7].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [6] Dal Pra, 2022, Validation of the decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy: an ancillary study of the SAKK 09/10 randomized clinical trial, Ann Oncol source
Checked before — its earlier verdict is held back until a new check runs.
- cites [7] Spratt, 2023, Genomic classifier performance in intermediate-risk prostate cancer: results from NRG Oncology/RTOG 0126 randomized phase 3 trial, Int J Radiat Oncol Biol Phys source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
PremisecitationImplementation barriers include clinician uncertainty about assay interpretation, inconsistent reimbursement, insufficient decision support, and poorly defined handoffs between oncology, pathology, genetics, and supportive care teams.
“Implementation barriers also include clinician uncertainty about assay interpretation, inconsistent reimbursement, insufficient decision support, and poorly defined handoffs between oncology, pathology, genetics, and supportive care teams [23, 24].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [23] Chen, 2024, Patient navigation in cancer treatment: a systematic review, Curr Oncol Rep source
Not checked in the free run.
- cites [24] Garfield, 2022, Evaluating the sustainability of patient navigation programs in oncology, Cancer source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
PremisecitationContemporary studies demonstrate that ctDNA can complement tissue sequencing, identify non-overlapping clinically relevant alterations, and capture dynamic tumor evolution during treatment.
“Contemporary studies demonstrate that circulating tumor DNA (ctDNA) can complement tissue sequencing, identify non-overlapping clinically relevant alterations, and capture dynamic tumor evolution during treatment [18, 19].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [18] Yang, 2024, Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer, iScience source
Checked before — its earlier verdict is held back until a new check runs.
- cites [19] Fonseca, 2024, Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer, Nat Commun source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
PremisecitationCurrent guidelines support both germline and somatic panel-based sequencing for men with metastatic prostate cancer because these tests can identify molecular alterations linked to approved or potentially actionable therapies.
“Current guidelines support both germline and somatic panel-based sequencing for men with metastatic prostate cancer because these tests can identify molecular alterations linked to approved or potentially actionable therapies [2, 3].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationProMark is a proteomic assay that measures protein expression using immunofluorescence-based techniques, reflecting downstream biological activity.
“In contrast, ProMark is a proteomic assay that measures protein expression using immunofluorescence-based techniques, reflecting downstream biological activity [4, 14].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [4] Ingrosso, 2022, Prognostic genomic tissue-based biomarkers in the treatment of localized prostate cancer, J Pers Med source
Checked before — its earlier verdict is held back until a new check runs.
- cites [14] Blume-Jensen, 2015, Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer, Clin Cancer Res source
May combine two claims.
PremisecitationMismatch repair deficiency and MSI-H status represent a predictive axis in prostate cancer; although relatively uncommon, these tumors may derive substantial benefit from immune checkpoint inhibitors, particularly pembrolizumab.
“Mismatch repair deficiency and MSI-H status represent another predictive axis. Although relatively uncommon, these tumors may derive substantial benefit from immune checkpoint inhibitors, particularly pembrolizumab [10].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [10] Lenis, 2024, Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer, Clin Cancer Res source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
PremisecitationMore recent systematic review evidence supports ctDNA as a promising precision oncology biomarker while emphasizing the need for assay standardization, improved reporting practices, and validation in more diverse populations.
“More recent systematic review evidence supports ctDNA as a promising precision oncology biomarker while emphasizing the need for assay standardization, improved reporting practices, and validation in more diverse populations [20].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [20] Spratt, 2023, Artificial intelligence predictive model for hormone therapy use in prostate cancer, NEJM Evid source
Not checked in the free run.
May combine two claims.
PremisereasoningCurrent evidentiary standards emphasize validation across independent cohorts, association with clinically meaningful endpoints, and demonstration of clinical utility.
“These limitations have informed current evidentiary standards, which emphasize validation across independent cohorts, association with clinically meaningful endpoints, and demonstration of clinical utility.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationTraditional risk stratification using prostate-specific antigen, grade group, and stage incompletely captures tumor biology and does not fully explain heterogeneity within nominal clinical risk groups.
“Traditional risk stratification using prostate-specific antigen, grade group, and stage remains indispensable; however, these measures incompletely capture tumor biology and do not fully explain the heterogeneity observed within nominal clinical risk groups [2, 3].”
Quote in the paperSubstantial claim0 of 2 sources checked
The paper relies on this without support.
The misalignment between biomarker function and clinical decision context contributes to both overuse and underuse of genomic testing in practice.
“This disconnect contributes to both overuse and underuse of genomic testing in practice.”
The paper relies on this without support.
A decision-oriented framework that aligns genomic testing with specific clinical actions will improve clinical utility, actionability, and patient outcomes.
“A clinically useful framework for prostate cancer genomics must therefore move beyond cataloging tests and instead clarify when genomic results change management, where evidence remains immature, and how implementation strategies can improve equity and actionability.”
“Such alignment shifts the focus from the availability of genomic data to its actionability, emphasizing that the value of genomic testing lies not in risk prediction alone but in its capacity to change management in clearly defined clinical contexts.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
MRI claim cites a PARP-response study
MinorThe claim about population-based MRI and genomic testing cites [9], whose listed study concerns an HRD mutational signature and response to PARP inhibition.
“Population-based data suggest that prostate magnetic resonance imaging (MRI) and genomic testing influence treatment pathways differently, highlighting the need to consider these tools as complementary rather than interchangeable components of risk assessment [9].”
“9. Boiarsky D, Tewari AK, Gulhan DC, A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.”
Intermediate-risk AI study is cited as oligometastatic validation
MinorThe sentence describes a landmark study identifying intermediate-risk patients who benefit from added hormone therapy, but its citation [21] is listed as a validation study in oligometastatic disease. The bibliography lists an AI hormone-therapy study under [20].
“In a landmark study, a multimodal artificial intelligence model derived from digitized histopathology and clinical variables identified men with intermediate-risk disease most likely to benefit from the addition of short-term androgen deprivation therapy to radiotherapy [21].”
“21. Wang JH, Deek MP, Mendes AA, Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer.”
Decipher uptake claim cites an HRD review
MinorThe cited reference [8] is a review of homologous recombination repair deficiency, not national data on Decipher use.
“National data indicate that use of genomic assays such as Decipher has increased in the United States, but uptake remains uneven and may reflect payer, practice, and regional differences rather than purely evidence-driven diffusion [8].”
“8. Piombino C, Homologous recombination repair deficiency in metastatic prostate cancer: new therapeutic opportunities.”
ASTuTE protocol claim cites an NGS-disparities study
MinorThe cited reference [22] is listed as a study of next-generation sequencing trends and disparities, not a prospective ASTuTE implementation protocol.
“Subsequent validation in oligometastatic castration-sensitive disease and the prospective ASTuTE implementation protocol suggest that AI-based biomarkers may ultimately influence treatment decisions across multiple disease states, provided that external validation, workflow integration, and real-world utility are demonstrated [22].”
“22. Hage Chehade C, Jo Y, Gebrael G, Trends and disparities in next-generation sequencing in metastatic prostate and urothelial cancers.”
ctDNA systematic-review claim cites an AI study
MinorReference [20] is listed as an artificial-intelligence model for hormone therapy use, not a systematic review of ctDNA.
“More recent systematic review evidence supports ctDNA as a promising precision oncology biomarker while emphasizing the need for assay standardization, improved reporting practices, and validation in more diverse populations [20].”
“20. Spratt DE, Tang S, Sun Y, Artificial intelligence predictive model for hormone therapy use in prostate cancer.”
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505 · see citing works
Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,468 · see citing works
Klein, E. A., Cooperberg, M. R., Magi‐Galluzzi, C., Simko, J., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 662 · see citing works
Cullen, J., Rosner, I. L., Brand, T. C., Zhang, N., Tsiatis, A. C., Moncur, J., Ali, A., Chen, Y., Knezevic, D., Maddala, T., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.11.030 · Cited by 278 · see citing works
Simon, R. (2010) · Personalized Medicine · doi:10.2217/pme.09.49 · Cited by 177 · see citing works
Blume-Jensen, P., Berman, D. M., Rimm, D. L., Shipitsin, M., Putzi, M., Nifong, T. P., Small, C., Choudhury, S., Capela, T., Coupal, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2603 · Cited by 158 · see citing works
Artificial intelligence predictive model for hormone therapy use in prostate cancer
Spratt, D. E., Tang, S., Sun, Y., Huang, H.-C., Chen, E., Mohamad, O., Armstrong, A. J., Tward, J. D., Nguyen, P. L., Lang, J. M., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300023 · Cited by 153 · see citing works
Patient Navigation in Cancer Treatment: A Systematic Review
Chen, M., Wu, V. S., Falk, D., Cheatham, C., Cullen, J., & Hoehn, R. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01514-9 · Cited by 153 · see citing works
Fonseca, N. M., Maurice-Dror, C., Herberts, C., Tu, W., Fan, W., Murtha, A. J., Kollmannsberger, C., Kwan, E. M., Parekh, K., Schönlau, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45475-w · Cited by 148 · see citing works
Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Spratt, D. E., Srinivas, S., Adra, N., Ahmed, B., An, Y., Bitting, R., Chapin, B., Cheng, H. H., Cho, S. Y., D’Amico, A. V., et al. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.0052 · Cited by 146 · see citing works
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 137 · see citing works
Lenis, A. T., Ravichandran, V., Brown, S., Alam, S. M., Katims, A., Truong, H., Reisz, P. A., Vasselman, S., Nweji, B., Autio, K. A., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3403 · Cited by 79 · see citing works
Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline
Yu, E. Y., Rumble, R. B., Agarwal, N., Cheng, H. H., Eggener, S. E., Bitting, R. L., Beltran, H., Giri, V. N., Spratt, D., Mahal, B., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02608 · Cited by 63 · see citing works
Dal Pra, A., Ghadjar, P., Hayoz, S., Liu, V. Y. T., Spratt, D. E., Thompson, D. J. S., Davicioni, E., Huang, H.-C., Zhao, X., Liu, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.007 · Cited by 52 · see citing works
Spratt, D. E., Liu, V. Y. T., Michalski, J., Davicioni, E., Berlin, A., Simko, J. P., Efstathiou, J. A., Tran, P. T., Sandler, H. M., Hall, W. A., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.04.010 · Cited by 44 · see citing works
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers
Hage Chehade, C., Jo, Y., Gebrael, G., Tripathi, N., Sayegh, N., Chigarira, B., Mathew Thomas, V., Galarza Fortuna, G., Narang, A., Campbell, P., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23186 · Cited by 43 · see citing works
Ver Hoeve, E. S., Simon, M. A., Danner, S. M., Washington, A. J., Coples, S. D., Percac‐Lima, S., Whited, E. C., Paskett, E. D., Naughton, M. J., Gray, D. M., et al. (2022) · Cancer · doi:10.1002/cncr.34251 · Cited by 24 · see citing works
Wang, J. H., Deek, M. P., Mendes, A. A., Song, Y., Shetty, A., Bazyar, S., Van der Eecken, K., Chen, E., Showalter, T. N., Royce, T. J., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110618 · Cited by 24 · see citing works
Varanasi, A. P., Burhansstipanov, L., Dorn, C., Gentry, S., Capossela, M. A., Fox, K., Wilson, D., Tanjasiri, S., Odumosu, O., & Saavedra Ferrer, E. L. (2024) · Cancer · doi:10.1002/cncr.35147 · Cited by 22 · see citing works
Genomic classifiers and prognosis of localized prostate cancer: a systematic review
Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., Rompre-Broduer, A., Lunyera, J., Basher, F., Bitting, R. L., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00766-z · Cited by 20 · see citing works
Mitchell, J., Camacho, N., Shea, P., Stopsack, K. H., Joseph, V., Burren, O. S., Dhindsa, R. S., Nag, A., Berchuck, J. E., O’Neill, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56944-1 · Cited by 16 · see citing works
Piombino, C., Pipitone, S., Tonni, E., Mastrodomenico, L., Oltrecolli, M., Tchawa, C., Matranga, R., Roccabruna, S., D’Agostino, E., Pirola, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094624 · Cited by 15 · see citing works
Garfield, K. M., Franklin, E. F., Battaglia, T. A., Dwyer, A. J., Freund, K. M., Wightman, P. D., & Rohan, E. A. (2022) · Cancer · doi:10.1002/cncr.33932 · Cited by 12 · see citing works
Prognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer
Ingrosso, G., Alì, E., Marani, S., Saldi, S., Bellavita, R., & Aristei, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010065 · Cited by 9 · see citing works
Yang, B., Zhao, T., Dong, B., Chen, W., Yang, G., Xie, J., Guo, C., Wang, R., Wang, H., Huang, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108931 · Cited by 9 · see citing works
Boiarsky, D., Tewari, A. K., Gulhan, D. C., Bakouny, Z., Ananda, G., Savignano, H., Lakshminarayanan, G., McClure, H. M., Silver, R., Choueiri, T. K., et al. (2024) · The Prostate · doi:10.1002/pros.24788 · Cited by 4 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Klein, 2014, A 17-gene assay to predict prostate cancer aggressiveness in men with early-stage disease, Eur Urol, 65, e89
Cited by
Sorted by citations
Sung, W. (2026) · Urological Science · doi:10.1097/us9.0000000000000146
- Authors
- Cobran, E. K., Samadder, N. J., Schaid, D. J., Conti, D. V., Haiman, C., Vargas, L., Gionfriddo, M. R., & Tilburt, J. C.
- Affiliations
- Mayo Clinic (US)
- University of Southern California (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Cobran, Ewan K.
- ORCID
- Venue
- Cancer Genetics
- Publisher
- Elsevier BV
- Published
- 2026-09
- Volume
- 306-307
- Pages
- 63-68
- ISSN
- 2210-7762 (ISSN-L)
- PMC
- PMC13425411
- OpenAlex
- W7163521587
- Semantic Scholar
- 45f458b14680ca36d03afbd6f37b768c7a168996
- Cited by
- 1
- References
- 24
- Citations by year
- 2026: 1
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 279 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cancer Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health National Cancer Institute (1K01CA230193)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- prostate cancer, genomic testing, localized prostate cancer, biochemical recurrence, metastatic prostate cancer, germline genetic testing, circulating tumor DNA, liquid biopsy, homologous recombination deficiency, mismatch repair deficiency, digital pathology, multimodal integration, reimbursement, patient-centered communication
- MeSH terms
- Artificial Intelligence, Genetic Testing, Humans, Male, Prognosis, Prostatic Neoplasms, Biomarkers, Tumor, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-06.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
